• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Sepsis (2067)
Event Type  Injury  
Event Description
Septic unspecified knee [arthritis bacterial].Case narrative: (b)(4) is a serious spontaneous case received from a physician via sales representative in united states.This report concerns a patient (no identifiers reported) who experienced septic unspecified knee during treatment with euflexxa (sodium hyaluronate) solution for injection unknown concentration, dose, route and frequency for an unknown indication from (b)(6) 2020 to an unknown stop date.The physician reported the patient developed septic unspecified knee after undergoing series of euflexxa injections two weeks ago (on (b)(6) 2020).No additional information the septic unspecified knee was medically significant.Action taken with euflexxa was unknown.At the time of this report, the outcome of septic unspecified knee was unknown.No concomitant medication was reported.All events in the case were reported as serious.At the time of reporting the case outcome was unknown.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: not related.Other case numbers: internal # - others = (b)(4).This ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.Ferring's sender comment: despite the limited information about the patient's medical and concomitant medications history, therapy details for euflexxa (indication of use, stop date, and route of adminstration) and event details (clinical course, event onset date, and outcome), association of euflexxa to septic joint event is unrelated due to lack of biological plausibility.The event is more likely due to incorrect guidelines for clean aseptic procedure of injection or underlying bacterial infection which were not reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1%  SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
pob 571, be'er tuvia industria
l zone
kiryat malachi 83104 02
IS  8310402
MDR Report Key16438979
MDR Text Key310231501
Report Number0002244564-2020-00011
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)Y
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Physician
Type of Report Initial
Report Date 02/23/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Event Location Other
Initial Date Manufacturer Received Not provided
Initial Date FDA Received02/24/2023
Type of Device Usage A
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Other;
-
-